Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis: A randomized, double-blind, placebo-controlled trial

Annals of Internal Medicine

Volumn 137, Issue 11, 2002, Pages 875-883

  Greenspan, Susan L ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Emkey, Ronald D ^{a,b,c,d,e,f,g,h,i,j,k,l}   Bone III, Henry G ^{a,b,c,d,e,f,g,h,i,j,k,l}   Weiss, Stuart R ^{a,b,c,d,e,f,g,h,i,j,k,l}   Bell, Norman H ^{a,b,c,d,e,f,g,h,i,j,k,l}   Downs Jr , Robert W ^{a,b,c,d,e,f,g,h,i,j,k,l}   McKeever, Clark ^{a,b,c,d,e,f,g,h,i,j,k,l}   Miller, Sam S ^{a,b,c,d,e,f,g,h,i,j,k,l}   Davidson, Michael ^{a,b,c,d,e,f,g,h,i,j,k,l}   Bolognese, Michael A ^{a,b,c,d,e,f,g,h,i,j,k,l}   Mulloy, Anthony L ^{a,b,c,d,e,f,g,h,i,j,k,l}   Heyden, Norman ^{a,b,c,d,e,f,g,h,i,j,k,l}   Wu, Mei ^{a,b,c,d,e,f,g,h,i,j,k,l}   Kaur, Amarjot ^{a,b,c,d,e,f,g,h,i,j,k,l}   Lombardi, Antonio ^{a,b,c,d,e,f,g,h,i,j,k,l}  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b RADIANT RESEARCH   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d Michigan Bone and Mineral Clinic   (United States)

^e S Diego Endocr and Medical Clinic   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^h Research for Health   (United States)

ⁱ SAM Clinical Research Center   (United States)

^j Bethesda Health Research Center   (United States)

^k MEDICAL COLLEGE OF GEORGIA   (United States)

^l MERCK RESEARCH LABORATORIES   (United States)

^m UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM CARBONATE; CONJUGATED ESTROGEN; ESTROGEN; PLACEBO;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HIP; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPINE;

EID: 0037016032     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-137-11-200212030-00008     Document Type: Article

References (21)

1. Black DM, Cummings SR, karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women of existing verrebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535-41. [PMID: 8950879]
2. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999; 282:1344-52. [PMID: 10527181]
3. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637-45. [PMID: 10517716]
4. Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum. 1999;42:1246-54. [PMID: 10366118]
5. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab. 2000;85:231-6. [PMID: 10634392]
6. Lindsay R, Cosman F, Lobo RA, Walsh BW, Harris ST, Reagan JE, et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab. 1999;84:3076-81. [PM1D: 10487668]
7. Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab. 2000;85:720-6. [PMID: 10690882]
8. Ravnikar VA. Compliance with hormone therapy. Am J Obstet Gynecol. 1987;156:1332-4. [PMID: 3578453]
9. Christiansen C, Christensen MS, Transbøl I. Bone mass in postmenopausal women after withdrawal of oestrogen/gesragen replacement therapy. Lancet. 1981;1:459-61. [PMID: 6110089]
10. Lindsay R, Hart DM, Forrest C, Baird C. Prevention of spinal osteoporosis in oophorectomised women. Lancet. 1980;2:1151-4. [PMID: 6107766]
11. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. JAMA. 1996;276:1389-96. [PMID: 8892713]
12. Stock JL, Ben NH, Chesnut CH 3rd, Ensrud KE, Genant HK, Harris ST, et al. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med. 1997;103:291-7. [PMID: 9382121]
13. Neter J, Wasserman W, Kutner M. Applied Linear Statistical Models. Boston: Richard D. Irwin; 1990.
14. Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PW, Anderson JJ. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med. 1993;329:1141-6. [PMID: 8377776]
15. Michaëlsson K, Baron JA, Farahmand BY, Johnell O, Magnusson C, Persson PG, et al. Hormone replacement therapy and risk of hip fracture: Population based case-control study. The Swedish Hip Fracture Study Group. BMJ. 1998;316:1858-63. [PMID: 9632404]
16. Kiel DP, Felson DT, Anderson JJ, Wilson PW, Moskowitz MA. Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study. N Engl J Med. 1987;317:1169-74. [PMID: 3657888]
17. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 1995;122:9-16. [PMID: 7985914]
18. Eastell R, Mallinak N, Weiss S, Ettinger M, Pettinger M, Cain D, et al. Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women. J Bone Miner Res. 2000;15:594-8. [PMID: 10750575]
19. Miller PD, Baran DT, Bilezikian JP, Greenspan SL, Lindsay R, Riggs BL, et al. Practical clinical application of biochemical markers of bone turnover: Consensus of an expert panel. J Clin Densitom. 1999;2:323-42. [PMID: 10548827]
20. Greenspan SL, Dresner-Pollak R, Parker RA, London D, Ferguson L. Diurnal variation of bone mineral turnover in elderly men and women. Calcif Tissue Int. 1997;60:419-23. [PMID: 9115158]
21. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res. 1996;11:1531-8. [PMID: 8889854]